SCHEMBL5113817

SCHEMBL5113817

CC(=O)C(CC(=O)OCc1ccccc1)NC(=O)C1CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PSMB5 P28074 2/20 0.47
ALDH1A1 P00352 2/20 0.46
USP30 Q70CQ3 1/20 0.45
CYP2C19 P33261 1/20 0.45
MMP9 P14780 1/20 0.45
LMNA P02545 2/20 0.45
CASP3 P42574 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
CTSV O60911 2/20 0.44
CTSL P07711 2/20 0.44
CTSS P25774 2/20 0.44
CTSK P43235 1/20 0.44
CCR5 P51681 1/20 0.44
EPHX1 P07099 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118218 0.91 LMNA (0.49) MEN1KMT2AL3MBTL1PSMB5ALDH1A1
SCHEMBL25491972 0.87 S1PR1 (0.49) L3MBTL1PSMB5ALDH1A1MMP9LMNA
SCHEMBL21678984 0.84 HTT (0.47) MEN1KMT2APSMB5ALDH1A1CYP2C19
SCHEMBL6990743 0.82 CASP3 (0.46) L3MBTL1LMNACASP3TDP1EPHX1
SCHEMBL8682005 0.82 L3MBTL1 (0.58) MEN1KMT2AL3MBTL1PSMB5ALDH1A1
SCHEMBL30826538 0.81 TMPRSS15 (0.46) ALDH1A1MMP9LMNATDP1
SCHEMBL5673271 0.81 TACR1 (0.53) MEN1KMT2AL3MBTL1ALDH1A1MMP9
SCHEMBL18775045 0.81 PSMB5 (0.60) MEN1KMT2APSMB5ALDH1A1CTSL
SCHEMBL24832472 0.81 L3MBTL1 (0.53) MEN1KMT2AL3MBTL1PSMB5ALDH1A1
SCHEMBL18791071 0.81 PSMB5 (0.60) MEN1KMT2APSMB5ALDH1A1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345070-B2 Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid ELI LILLY AND COMPANY (US) 2008-03-18 US disclosed
EP-1313716-B1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS LILLY CO ELI (US) 2007-05-02 EP disclosed
US-20050245584-A1 Peroxisome proliferator activated receptor agonists BROOKS DAWN A 2005-11-03 US disclosed
US-6930120-B2 Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists ELI LILLY AND COMPANY (US) 2005-08-16 US disclosed
US-20040097590-A1 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists BROOKS DAWN ALISA (US) 2004-05-20 US disclosed
EP-1313716-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2003-05-28 EP disclosed
WO-2002016331-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097590-A1 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists PPARA, PPARG, PPARD MEN1 4878/4885KMT2A 3023/4885L3MBTL1 2655/4885
US-20050245584-A1 Peroxisome proliferator activated receptor agonists PPARG, PPARA, PPARD MEN1 4883/4885KMT2A 3166/4885L3MBTL1 2683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.